CCCC
C4 Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.92 / 10
Netural
Money flow is good (7.83/10) with positive large and extra-large inflows, offsetting smaller outflows. Analyst consensus is bullish (Strong Buy/Buy), yet their historical win rate is 0%, indicating unreliable forecasts. Sentiment is neutral overall.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-17
InstitutionBarclays
Times predicted3
Historical Win Rate0.0%
What is the analyst consensus for CCCC?
- CCCC holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.92/10 (Netural).
